Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.18 Average PT from Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eighteen analysts that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $30.18.

Several analysts have issued reports on the company. Wall Street Zen lowered Nurix Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Needham & Company LLC reissued a "buy" rating and issued a $27.00 target price on shares of Nurix Therapeutics in a report on Tuesday, April 29th. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a research report on Monday, March 17th. Finally, Wells Fargo & Company decreased their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th.

Insider Activity

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,438 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $28,037.00. Following the completion of the sale, the chief financial officer now owns 39,922 shares of the company's stock, valued at $459,103. This trade represents a 5.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of the business's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the transaction, the insider now owns 61,516 shares of the company's stock, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,013 shares of company stock valued at $137,096. 7.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company grew its stake in Nurix Therapeutics by 2.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company's stock worth $585,000 after acquiring an additional 642 shares in the last quarter. Corebridge Financial Inc. grew its stake in Nurix Therapeutics by 2.3% in the fourth quarter. Corebridge Financial Inc. now owns 34,907 shares of the company's stock worth $658,000 after purchasing an additional 770 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in Nurix Therapeutics by 0.7% during the 4th quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company's stock worth $2,159,000 after purchasing an additional 785 shares during the period. US Bancorp DE raised its position in Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after purchasing an additional 842 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its holdings in shares of Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after buying an additional 877 shares during the period.

Nurix Therapeutics Stock Down 0.3%

Shares of Nurix Therapeutics stock traded down $0.03 during trading hours on Tuesday, reaching $11.93. 778,950 shares of the stock traded hands, compared to its average volume of 882,847. The company has a 50 day moving average price of $10.56 and a 200 day moving average price of $15.12. Nurix Therapeutics has a one year low of $8.18 and a one year high of $29.56. The firm has a market capitalization of $909.50 million, a price-to-earnings ratio of -4.13 and a beta of 2.15.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The business had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. During the same period in the prior year, the company earned ($0.76) earnings per share. Sell-side analysts anticipate that Nurix Therapeutics will post -2.99 earnings per share for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.